肿瘤微环境
CD8型
细胞毒性T细胞
效应器
免疫疗法
癌症研究
免疫系统
免疫检查点
癌症免疫疗法
T细胞
免疫学
医学
生物
细胞生物学
体外
生物化学
作者
Mark J. Bucsek,Guanxi Qiao,Cameron R. MacDonald,Thejaswini Giridharan,Lauren Evans,Brian Niedzwecki,Haichao Liu,Kathleen M. Kokolus,Jason W.‐L. Eng,Michelle N. Messmer,Kristopher Attwood,Scott I. Abrams,Bonnie L. Hylander,Elizabeth A. Repasky
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2017-08-18
卷期号:77 (20): 5639-5651
被引量:193
标识
DOI:10.1158/0008-5472.can-17-0546
摘要
The immune context of tumors has significant prognostic value and is predictive of responsiveness to several forms of therapy, including immunotherapy. We report here that CD8+ T-cell frequency and functional orientation within the tumor microenvironment is regulated by β2-adrenergic receptor (β-AR) signaling in host immune cells. We used three strategies-physiologic (manipulation of ambient thermal environment), pharmacologic (β-blockers), and genetic (β2-AR knockout mice) to reduce adrenergic stress signaling in two widely studied preclinical mouse tumor models. Reducing β-AR signaling facilitated conversion of tumors to an immunologically active tumor microenvironment with increased intratumoral frequency of CD8+ T cells with an effector phenotype and decreased expression of programmed death receptor-1 (PD-1), in addition to an elevated effector CD8+ T-cell to CD4+ regulatory T-cell ratio (IFNγ+CD8+:Treg). Moreover, this conversion significantly increased the efficacy of anti-PD-1 checkpoint blockade. These data highlight the potential of adrenergic stress and norepinephrine-driven β-AR signaling to regulate the immune status of the tumor microenvironment and support the strategic use of clinically available β-blockers in patients to improve responses to immunotherapy. Cancer Res; 77(20); 5639-51. ©2017 AACR.
科研通智能强力驱动
Strongly Powered by AbleSci AI